Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy

Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy

Submitted by admin on February 25, 2022 - 9:58am
Source: 
Pharmaceutical Business Review
News Tags: 
Boehringer Ingelheim
idiopathic pulmonary fibrosis
FDA
BI 1015550
breakthrough status
Headline: 
Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy
snippet: 


The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Boehringer Ingelheim’s new oral therapy, BI 1015550, to treat patients with idiopathic pulmonary fibrosis (IPF).

Do Not Allow Advertisers to Use My Personal information